Clinical Trial Update: MT2014-14 IT-MSC for Advanced Cerebral Adrenoleukodystrophy (cALD) [Phase 1]

View source ↗

Summary

A Phase 1 trial of MT2014-14 IT-MSC for advanced cerebral adrenoleukodystrophy has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cerebral Adrenoleukodystrophy

Drugs mentioned

• MT2014-14 IT-MSC

Snippet

Sponsor: Masonic Cancer Center, University of Minnesota | Conditions: Cerebral Adrenoleukodystrophy | Phase 1 | Status: WITHDRAWN